Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Polycystic Ovary Syndrome 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Diabetes Mellitus, Type 2 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Thyroid Nodule 1Renal Insufficiency 1Pancreatic Neoplasms 1Neoplasms, Adipose Tissue 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Kidney Failure, Chronic 1Insulin Resistance 1Infertility 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Body Weight 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 78fludarabine phosphate 77Azacitidine 76Peripheral Blood Stem Cell Transplantation 63Busulfan 53Mycophenolic Acid 51Whole-Body Irradiation 50Tacrolimus 48Cytarabine 43Cyclosporine 43Methotrexate 37Decitabine 36Filgrastim 32Antilymphocyte Serum 30venetoclax 27Radiotherapy 25Melphalan 23fludarabine 22Etoposide 18Methylprednisolone 17Biopsy 15Cyclosporins 14Specimen Handling 13Injections 13Granulocyte Colony-Stimulating Factor 13Flow Cytometry 13Cord Blood Stem Cell Transplantation 13decitabine and cedazuridine drug combination 12Idarubicin 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Sitagliptin Phosphate × Clear all
NCT05895201 2024-04-29

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

Indiana University

Phase 1/2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡